Stephens Inc. AR Raises Position in Medtronic PLC $MDT

Stephens Inc. AR increased its stake in Medtronic PLC (NYSE:MDT) by 3.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 269,761 shares of the medical technology company’s stock after purchasing an additional 9,000 shares during the quarter. Stephens Inc. AR’s holdings in Medtronic were worth $25,692,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Delos Wealth Advisors LLC purchased a new position in Medtronic in the 2nd quarter worth approximately $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter worth $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medtronic in the third quarter valued at $33,000. Tripletail Wealth Management LLC purchased a new position in shares of Medtronic in the third quarter valued at $34,000. Finally, GFG Capital LLC acquired a new stake in Medtronic during the 2nd quarter valued at $36,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

MDT stock opened at $96.46 on Wednesday. The stock’s 50 day simple moving average is $98.56 and its 200 day simple moving average is $94.72. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a market cap of $123.67 billion, a P/E ratio of 26.00, a P/E/G ratio of 2.56 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. The firm’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MDT. Cowen reiterated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Barclays boosted their price target on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Finally, Stifel Nicolaus increased their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).